Correlation of imaging and plasma-based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC): A GOG 218 ancillary data analysis.

5507Background: Increasing measures of adiposity can correlate with poor oncologic outcomes and lack of response to antiangiogenic therapies. Limited data exists on the impact of subcutaneous fat and visceral fat density(SFD/ VFD) on oncologic outcomes. IL-6 has been suggested as a predictive serum biomarker for overall survival (OS) with use of bevacizumab (bev) in EOC. Methods: 1249 patients(pts) (67%) from GOG 218 with imaging measurements were included in the OS analysis. Predictive analyses for bev responsiveness used pts who received chemotherapy (CT) + placebo and placebo maintenance and CT + bev and bev maintenance (851 pts). Of these, 522 pts (61%) had IL-6 measurements. SFD and VFD were calculated utilizing Hounsfield units (HU). Proportional hazards models were used to assess the association between BMI, SFD, and VFD with OS. Spearman correlation was used to assess the relationship between IL-6 and VFD. Results: Demographic characteristics for pts included in this analysis did not differ from t...